Class action settlement
VSL Pharmaceuticals, Inc.
About this settlement
VSL#3 probiotic falsely marketed as clinically proven effective
Summary
Plaintiffs allege VSL Pharmaceuticals, Leadiant Biosciences, and Alfasigma USA falsely represented that VSL#3 probiotic sold between June 1, 2016 and June 19, 2019 had been proven in clinical tests to be effective for certain medical conditions, and that consumers overpaid as a result. Defendants deny wrongdoing but agreed to a settlement to resolve the claims. Defendants agreed to pay $20 million to create a settlement fund. Class members who submit a valid claim may receive $20 per unit of VSL#3 purchased, subject to pro rata adjustment. The case is Starr v. VSL Pharmaceuticals, Inc., Case No. 8:19-cv-02173-LKG, in the U.S. District Court for the District of Maryland.
Who qualifies
You are a Settlement Class Member if you purchased VSL#3 in the United States between June 1, 2016 and June 19, 2019. Excluded are officers or directors of Defendants (VSL, Leadiant, Alfasigma) or their parents, subsidiaries, or affiliates, and any entity in which Defendants have a controlling interest. Also excluded are persons or entities that purchased VSL#3 exclusively for resale to a consumer. Judges assigned to the case, their staff or immediate family, and Class Counsel and their staff are also excluded.
Suits does not handle payments or process claims. Payments are issued by the claim administrator and typically take 3-6 months.